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Due to their compact genome size, fast replication and
high mutation rate, viruses evolve swiftly, enabling rapid
adaptation to selective pressures, including antiviral drugs.
RNA viruses evolve at particularly high rates due to the
inherent low fidelity of their replication machinery. The
hepatitis C virus (HCV) is no exception, as demonstrated
by its high genetic diversity. HCV infects about 3% of the
world population and causes a chronic liver disease in the
majority of the infected individuals (McHutchison, 2004).
There is no vaccine available for HCV and the current
therapy, based on interferon-α (IFN) and ribavirin (RBV),
is inconvenient, poorly tolerated and of limited efficacy, in
particular for genotype 1 patients. Therefore, the develop-
ment of new therapeutic agents to treat HCV infection is
considered of paramount importance.
Similar to the human immunodeficiency virus (HIV)
and the hepatitis B virus (HBV) antiviral research, efforts
to develop new therapeutic agents for HCV have mostly
focused on the discovery of direct antiviral agents which
inhibit HCV replication by targeting the viral enzymes.
The HCV polymerase has been regarded as a promising
target for discovering novel antiviral agents, based on the
clinical success of anti-HIV and anti-HBV drugs directed
at the cognate enzymes. Development of HCV polymerase
inhibitors has been significantly delayed by the lack of
animal models and appropriate cell culture systems.
Nonetheless, a decade of efforts from several biopharma-
ceutical laboratories has resulted in the identification of
numerous classes of potent and selective inhibitors, the
most advanced of which are progressing in clinical trials. As
these new agents are approaching clinical use, scientists are
beginning to anticipate the next big challenge in HCV-
drug discovery, namely the emergence of resistant viruses.
Indeed, the ultimate clinical success of HCV polymerase
inhibitors depends on their ability to suppress all viral vari-
ants and prevent the emergence of resistant viruses.
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The high prevalence of the disease caused by
hepatitis C virus (HCV) and the limited efficacy of
interferon-based therapies have stimulated the
search for safer and more effective drugs. The
development of inhibitors of the HCV NS5B RNA
polymerase represents a promising strategy for
identifying novel anti-HCV therapeutics. However,
the high genetic diversity, mutation rate and
turnover of HCV are expected to favour the emer-
gence of drug resistance, limiting the clinical
usefulness of polymerase inhibitors. Thus, the
characterization of the drug-resistance profile of
these antiviral agents is considered crucial for
identifying the inhibitors with a higher probability
of clinical success. In the absence of an efficient 
in vitro infection system, HCV sub-genomic repli-
cons have been used to study viral resistance to
both nucleoside and non-nucleoside NS5B
inhibitors. While these studies suggest that drug-
resistant viruses are likely to evolve in vivo, they
provide a wealth of information that should help
in the identification of inhibitors with improved
and distinct resistance profiles that might be used
for combination therapy.
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As exemplified by HIV and HBV, resistance to antiviral
therapy has become a major determinant in the manage-
ment of chronic viral infections. Therefore efforts to assess
resistance development and define the effect of inhibitors
on different viral genotypes are now viewed as integral
parts of antiviral drug discovery, even in the early stages of
drug development. As described below, the advent of a
robust in vitro replication system has both changed the
scenario of HCV research and accelerated drug discovery
efforts.
In this review, we summarize the findings in the
emerging field of HCV antiviral resistance, focusing specif-
ically on characterizing the molecular determinants of
resistance to inhibitors of the NS5B polymerase.
HCV epidemiology and natural history
HCV was identified as the agent responsible for the
majority of blood-borne hepatitis approximately 15 years
ago and is still one of the leading causes of chronic liver
disease throughout the world (Choo et al., 1989;
Houghton, 1996). It has been estimated that HCV infects
more than 170 million persons worldwide, with population
prevalence ranging from 1–5% in most countries (Wasley
& Alter, 2000). The incidence of new infections has
declined significantly after the introduction of tests to
identify contaminated blood in the early 1990s, and nowa-
days well over half of new cases are acquired as the result of
injection-drug use (McHutchison, 2004). HCV displays a
high degree of genetic heterogeneity and, based on
sequence analysis, can be classified into six major genotypes
(designated 1–6) with >100 subtypes (designated a, b, c and
so on) (Simmonds et al., 1993). In addition, even viral
sequences derived from the same infected individual
exhibit such a considerable diversity to be defined as quasi-
species. The various genotypes differ by more than 30% in
their nucleotide sequence and have a different geographical
distribution: genotypes 1, 2 and 3 account for more than
90% of the infections in western countries, with genotype 1
being predominant in the US, Europe and Japan.
Genotypes 4, 5 and 6 are very rare in these countries but are
predominant in other areas such as Egypt (genotype 4),
South Africa (genotype 5) and southeast Asia (genotype 6).
Acute HCV infection is usually asymptomatic and
therefore it is only seldom diagnosed. Only a minority of
patients infected with HCV resolve acute infection sponta-
neously and more than 60% of infected individuals develop
a slowly progressive chronic disease characterized by liver
fibrosis and non-specific symptoms (McHutchison, 2004).
The late sequelae of HCV infection include chronic
hepatitis, cirrhosis, liver failure and occasionally hepatocel-
lular carcinoma. Although average life-expectancy of
chronic HCV patients is not dissimilar from that of the
uninfected population, chronic HCV infection accounts for
significant morbidity and calls for better treatment for
many patients.
Current treatments
Treatment of chronic HCV infection is aimed at cure.
Indeed, the main goal of therapy is to produce a sustained
virological response (SVR) (no detectable viraemia
6 months following cessation of therapy) which is believed
to correlate with complete resolution of the disease (Bacon,
2004). Limited epidemiological studies indicate that also a
partial virological response accompanied by improvement
in hepatic histology is associated with decreased risk of
progression to cirrhosis and hepatocellular carcinoma
(Poynard et al., 2002). Current HCV therapies are based on
different forms of interferon-α (IFNs) and have undergone
impressive advances in the last decade, in particular with
the introduction of pegylated forms of IFN (pIFNs) with
improved  pharmacokinetic (PK) properties (Chander et
al., 2002; Di Bisceglie & Hoofnagle, 2002). IFNs and
pIFNs are moderately effective as monotherapy and are
administered via subcutaneous injection. In the standard
clinical practice, pIFNs are replacing unmodified IFNs
mostly because of slightly better SVR rates and the conve-
nience of a less frequent administration (once a week vs
three times a week). RBV is a nucleoside analogue and is
administered orally once a day. RBV does not have a clear
antiviral effect as a monotherapy but doubles the response
rates of IFN therapy. The best clinical results are obtained
with pIFNs and RBV combination regimens. Duration of
therapy and response rates are genotype-dependent, there-
fore patients are routinely genotyped in order to select the
appropriate therapy protocol. SVR is obtained in ~45% of
HCV genotype 1-infected patients and in ~76–80% of
genotype 2 and 3-infected patients. Therapies based on
IFNs are poorly tolerated because of significant adverse
effects, ranging from mild flu-like symptoms to severe
haematological, neurological and psychiatric disorders.
Because of the limited efficacy and side effects, less than
20% of diagnosed patients undergo treatment.
HCV genomic organization and functions
of viral proteins
The molecular characterization of HCV became possible
with the cloning of the viral genome in 1989, which led to
its classification in a separate genus (Hepacivirus) of the
Flaviviridae, a family of positive strand RNA viruses that
include human and animal pathogens (Rice, 1996;
Houghton, 1996; Choo et al., 1989). The viral genome is a
9.6 kb-long messenger RNA molecule and has the canon-
ical structure of the Flaviviridae genomes, with a single
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open reading frame (ORF) flanked by two untranslated
regions (UTR) (Figure 1) (Choo et al., 1989). The 5′-UTR
is highly conserved between different virus genotypes and
contains an internal ribosome entry site (IRES) responsible
for cap-independent translation of the ORF, as well as
essential cis-acting replication elements (Tsukiyama-
Kohara et al., 1992, Friebe et al., 2001). The 3′-UTR
encompasses a variable domain of approximately 50
nucleotides, a poly-U sequence of variable length and a
highly conserved 98-base element essential for replication
(Tanaka et al., 1995; Friebe et al., 2001; Kolykhalov et al.,
1997). The ORF encodes a ~3000 amino acid polyprotein
that is cleaved co- and post-translationally by the concerted
action of cellular and viral proteases, resulting in the gener-
ation of at least 10 different mature viral proteins named as
follows: NH2-C-E1-E2-p7-NS2-NS3-NS4A-NS4B-
NS5A-NS5B-COOH (Figure 1A). The signal peptidase
and the signal peptide peptidase of the endoplasmic retic-
ulum (ER) release from the polyprotein the structural
proteins: Core (C), E1, E2, and the small transmembrane
peptide p7 (Santolini et al., 1994; Hijikata et al., 1993b;
McLauchlan et al., 2002). The structural proteins become
associated with (C) or integrated into (E1, E2 and p7) the
ER membrane and form functional oligomers that will
eventually promote virus budding. The non-structural (NS)
proteins are released from the nascent precursor by two
viral proteases (Figure 1). The NS proteins also become
associated with (NS3) or integrated into (NS2, NS4A,
NS4B, NS5A and NS5B) the ER membrane where they
interact with each other and with host proteins to form the
viral replication machinery.
The main role of the C protein is believed to be the
formation of the viral capsid, though expression of this
protein in mammalian cells has been reported to have
pleiotropic effects, including transcriptional modulation,
alteration of the lipid metabolism and effects on apoptosis
(McLauchlan, 2000). Interestingly, the Core coding
sequence also encodes, in an alternative ORF, a second
protein, termed ARFP or F (Walewski et al., 2001; Xu et
al., 2001) not strictly required for infectivity in cell culture
or in vivo (McMullan LK, Grakoui A, Puig M, Mihalik K,
Branch AD, Feinstone SM & Rice CM (2004) Multiple
stop codons in the HCV ARF suggest that expression of
F/ARF is not essential for virus replication but reveal a
functional RNA element. 11th International Symposium on
Hepatitis C Virus & Related Viruses, Heidelberg, Germany).
The E1 and E2 glycoproteins assemble as a noncovalent
heterodimer and are believed to be the viral envelope
components responsible for cell attachment and entry. In
fact, pseudo-typed retro- or lenti-viral particles harbouring
E1 and E2 in their envelope have been shown to infect
tissue culture cells of hepatic origin (Hsu et al., 2003;
Bartosch et al., 2003). E2 has been shown to recognize
several putative HCV receptors, including the tetraspannin
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CD81, the low-density lipoprotein receptor and the B-I
scavenger receptor (Pileri et al., 1998; Scarselli et al., 2002;
Flint et al., 2001). p7 is a small transmembrane protein and
has been recently shown to act as a cation-selective ion
channel (Griffin et al., 2003; Pavlovic et al., 2003; Sakai et
al., 2003).
Among the NS proteins, NS2 is an integral membrane
protein whose functions are not completely understood.
The C-terminal half of NS2 and the N-terminus of NS3
constitute the NS2-3 protease, a zinc-dependent auto-
protease responsible for a single cut between NS2 and NS3
(Pieroni et al., 1997; Hijikata et al., 1993a; Grakoui et al.,
1993b). NS3 is a multifunctional protein and probably the
most characterized HCV polypeptide. In addition to
forming the NS2-3 protease, the N-terminal domain of
NS3 together with the small NS4A peptide constitutes the
NS3-4A protease, a distinct serine protease that cleaves 
the polyprotein at the NS3/NS4A, NS4A/NS4B,
NS4B/NS5A and NS5A/NS5B junctions (Grakoui et al.,
1993a; Bartenschlager et al., 1993; Tomei et al., 1993)
(Figure 1). The C-terminal domain of NS3 contains an
NTPase/helicase necessary for translation and replication
of the HCV genome (Kim et al., 1995). NS4B is an inte-
gral membrane protein and contains a nucleotide binding
domain in its cytosolic region (Einav et al., 2004; Hugle et
al., 2001). NS4B expression in mammalian cells induces
characteristic membranous vesicles - the membranous web
- which are believed to be the site of viral replication
(Egger et al., 2002). NS5A is a highly phosphorylated
protein capable of binding one zinc ion (Tanji et al., 1995;
Tellinghuisen et al., 2004). Although mutational analysis
has revealed that zinc binding is essential for replication in
tissue culture, the role of NS5A in HCV replication
remains controversial. The presence of tissue culture adap-
tive mutations in NS5A has reinforced the belief that
NS5A might have a direct role in replication of the viral
RNA. In addition, experimental evidence suggests that
NS5A might also be involved in the resistance to the
antiviral effect of interferon (Tan & Katze, 2001). As
discussed below, NS5B is the RNA-dependent RNA poly-
merase (RdRp) and is the catalytic core of the viral repli-
case (Behrens et al., 1996).
HCV replicons
The lack of adequate laboratory animal models and the
inability to efficiently culture the virus in vitro have been
major obstacles in dissecting the HCV life cycle and in
establishing reliable antiviral assays. Only in recent years
have cell-based assays and pre-clinical animal systems such
as a tissue culture replication system, cDNA clones infec-
tious in the chimpanzee, and mouse models for HCV
infection been developed.
Undoubtedly, the major contribution to basic virology
studies and drug discovery has come from the development
of a reliable tissue culture replication system based on
subgenomic ‘replicons’. This system provided the long-
sought after cell-based model for evaluating antiviral
compounds as well as an in vitro genetic system for virology
and resistance studies (Bartenschlager, 2002). Replicons
are genetically modified HCV genomes capable of self-
replication in tissue culture cells. Based on experience
with other positive-strand RNA viruses, HCV replicons
were initially assembled with a bicistronic arrangement by
replacing the structural region of the genome of the Con1
isolate with the gene encoding the enzyme neomycin
phosphotransferase (NPT) and the IRES of the
encephalomyocarditis virus (EMCV, Figure 1B)
(Lohmann et al., 1999). In this arrangement, translation
of NPT is mediated by the HCV IRES present in the 5′
UTR, whereas the EMCV IRES promotes translation of
the HCV replication proteins. Transfection of these repli-
cons in the human hepatoma cell line Huh-7 followed by
selection with neomycin resulted in the isolation of cell
clones that supported very efficient replication of the
replicons. Subsequent studies showed that efficient repli-
cation required tissue-culture adaptive mutations in the
replicons and also led to the isolation of Huh-7 subclones
that supported HCV replication more efficiently (Blight
et al., 2000; Blight et al., 2002). These findings opened the
way to the development of new types of mono- and bi-
cistronic replicons expressing different selectable markers
and/or reporter genes. These novel replicons facilitated
HCV genetic studies and paved the way to the develop-
ment of high-throughput screening assays for the identi-
fication of novel inhibitors. The repertoire of available
replicons has subsequently been extended by the estab-
lishment of replicons derived from other viral isolates and
the identification of other cell lines that support HCV
replication (Ali et al., 2004; Date et al., 2004; Kato et al.,
2003; Zhu et al., 2003).
These improvements also led to the discovery that Huh-
7 cells supported replication of full-length HCV genomic
RNAs. Very recently, it has been shown that these features
can be exploited to produce recombinant viral particles that
can infect cultured cells (Lindenbach et al., 2005; Wakita et
al., 2005; Zhong et al., 2005). Strikingly, not all viral
sequences can be converted to replicons. The limited data
currently available suggest that there is no clear concor-
dance between replication in tissue culture and infectivity
in the chimpanzee and these properties may even be
inversely correlated. Indeed, the HCV isolates that repli-
cate to high titres in vivo replicate less efficiently or not at
all in tissue culture (for example HCV-con1, HCV-BK,
HCV-H77) unless one or more adaptive mutations
emerge. Conversely, it has been shown that at least some
L Tomei et al.
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cell culture adaptive mutations abolish or significantly
reduce infectivity in vivo (Bukh et al., 2002).
Tissue culture adaptive mutations have been described
in all non-structural HCV proteins, except for NS4A and
are thought to influence protein-protein interactions crit-
ical to modulating the activity of the HCV replication
complex or, alternatively, to affect virus ability to counteract
the innate cellular antiviral response.
NS5B RNA-dependent RNA polymerase
The NS5B RdRp is the catalytic core of the HCV replica-
tion machinery and is essential for viral replication. The
properties of this enzyme are different enough from those
of host RNA and DNA polymerases to make it likely that
specific inhibitors of the HCV enzyme will not inhibit the
cellular enzymes, and will therefore be devoid of toxic
effects.
The polymerase activity of the NS5B protein was
predicted from the presence of signature motifs in its
sequence (Choo et al., 1989) and was confirmed when the
recombinant full-length protein was purified and shown to
be capable of RNA synthesis in vitro (Behrens et al., 1996;
Lohmann et al., 1997). Subsequent biochemical and struc-
tural studies of the polymerase were facilitated by the
expression of more soluble and active forms of the enzyme
lacking the hydrophobic transmembrane anchor contained
within the last 21 amino acids (Tomei et al., 2000;
Lohmann et al., 1997; Ferrari et al., 1999). Interestingly,
though it is dispensable for the in vitro activity of the
recombinant NS5B enzyme, this C-terminal membrane
anchor is necessary for viral replication (Lee et al., 2004).
In vitro, the NS5B polymerase catalyses the synthesis of
RNA using homo- or hetero-polymeric RNA templates,
both with and without a primer. The enzyme does not have
strict requirements for the length and the sequence of the
template RNA, although preference for specific sequences,
including the HCV RNA, has been reported ( Johnson et
al., 2000; Oh et al., 2000; Shim et al., 2002; Kim et al.,
2002; Kao et al., 2000). As expected for an RdRp, NS5B
does not accept DNA as a template or deoxynucleotides
(dNTPs) as substrates. However, both oligo-ribonu-
cleotides and oligo-deoxyribonucleotides can be utilized as
primers by the HCV enzyme. In the absence of a primer,
NS5B initiates RNA synthesis by either using the 3′-
terminal-OH group of the template as primer, or by means
of an authentic de novo initiation mechanism using as
primer a nucleotide complementary to the base at the 3′
end of the template (Zhong et al., 2000; Luo et al., 2000;
Kim et al., 2002). Experimental evidence indicates that
de novo initiation has specific sequence requirements and
that the NS5B polymerase acts by the so-called prime and
realign mechanism, whereby the enzyme initially synthesizes
short leader RNAs during abortive polymerization and
subsequently uses these oligoribonucleotides as primers for
elongation (Zhong et al., 2000; Shim et al., 2002).
A major advance in the understanding of the NS5B
polymerase was provided by the resolution of the three-
dimensional structures of several truncated forms of the
apoenzyme and of complexes with nucleotides or RNA
templates (Adachi et al., 2002; Ago et al., 1999; Bressanelli
et al., 2002; Bressanelli et al., 1999; Lesburg et al., 1999;
O’Farrell et al., 2003). The NS5B has the canonical ‘right
hand’ shape, with the characteristic fingers, palm and
thumb sub-domains (Figure 2). Similarly to other RdRps,
the HCV polymerase has a compact shape due to the pres-
ence of two extended loops – the fingertips – that connect
the fingers and thumb domains and completely encircle the
active site cavity, to which the RNA template and the
nucleoside triphosphate (NTP) substrates have access
through two positively charged tunnels (Bressanelli et al.,
2002). The palm sub-domain constitutes the active site of
the molecule and contains the residues responsible for the
nucleotidyl transfer reaction within the D-(X)4-D and the
GDD motif. The thumb and the fingers sub-domains bind
the template and the incoming nucleotide and position
them for initiation and elongation. Two structural elements
peculiar to the NS5B structure are a β-hairpin (β-loop),
protruding from the thumb into the active site, and a C-
terminal region, located immediately before the transmem-
brane domain, that folds from the surface of the thumb
towards the active site and establishes a series of
hydrophobic interactions with a shallow pocket comprised
between the palm and thumb sub-domains (Adachi et al.,
2002). These elements are probably involved in positioning
the 3′ terminus of template RNA and are considered crucial
for template selection. Biochemical characterization of
deleted enzymes lacking either one of these elements has
confirmed that they play an important role in modulating
NS5B activity (Hong et al., 2001; Adachi et al., 2002).
Deletion of these elements increased primer-dependent
polymerase activity, suggesting that their function is to
favour de novo initiation of RNA synthesis from the 3′ end
of single-stranded template. The structure of the NS5B
polymerase in complex with nucleotides (Bressanelli et al.,
2002) lent further support to the role of these elements in
de novo-initiation. Three distinct nucleotide-binding sites
were observed in the catalytic centre of the HCV RdRp
whose geometry was remarkably similar to that observed in
the initiation complex of the RNA phage φ6 RdRp
(Butcher et al., 2001), strengthening the proposal that 
the two enzymes initiate de novo replication by similar
mechanisms.
The surface of the enzyme shows a number of sites that
are potentially involved in the interaction with other
components of the viral replication apparatus. A prominent
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feature revealed by crystallographic studies is the presence
of a non-catalytic GTP-binding site on the enzyme
surface, near the interface between fingers and thumb
domains (Bressanelli et al., 2002). This GTP pocket was
proposed to be an allosteric regulatory site whose occu-
pancy modulates the interactions between the two
domains, thus controlling the conformational changes
during the polymerization cycle. The presence of a unique
nucleotide-binding site distal from the active site poten-
tially provides an attractive target for allosteric inhibitors of
the HCV polymerase reaction. As discussed below, crystal-
lographic studies in the presence of inhibitors highlighted
the existence of two distinct allosteric binding sites, both
located in the thumb domain.
Methodological approaches to resistance
studies
Although experimental systems for HCV antiviral resis-
tance studies are less advanced than for HIV, recent
progress in biochemical and replicon assays have laid the
foundations for resistance testing during drug development
and eventually in therapy management.
The first and possibly most important requirement for
resistance profiling is the availability of cell-free and cell-
based assays for evaluating the activity of antiviral
compounds on a panel of viral isolates representative of
HCV genetic variability. Recombinant NS5B polymerases
from several different viral isolates have recently become
L Tomei et al.
Figure 2. X-ray crystallographic structure of the NS5B RNA-dependent RNA polymerase
The thumb, palm, and fingers domains are coloured in blue, green, and red, respectively. The two catalytic aspartates are shown in stick and
ball style in the active site. Residues responsible for resistance to the various inhibitors are shown in the CPK style and coloured according to
the resistance pattern: magenta (benzimidazoles/indoles), light blue (thiophenes), brown (benzothiadiazines), yellow (dihydroxypyrimidines),
and orange (2′-C-Me nucleosides).
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available to test the efficacy of antiviral agents in biochem-
ical assays and more will probably be at hand in the near
future (Carroll et al., 2004). The repertoire of reagents for
cell-based assays is also growing at a steady pace. To date,
replication-proficient HCV replicons have been derived
from a handful of genotype 1a, 1b and 2a viral strains.
While these replicons already provide an initial hint of the
variability of HCV responses to antiviral agents, the avail-
ability of more replicons will certainly increase the capacity
to predict drug efficacy in patients. Optimistically, efforts
to obtain new replicons from all clinically relevant geno-
types will be facilitated by the latest expansion of the reper-
toire of cell lines and clones permissive for replicon
replication as well as by the understanding of the role of
adaptive mutations. Another successful avenue towards
increasing the number of replicons available for testing
NS5B inhibitors is the assembly of chimeric replicons
derived from genotype 1 replication-competent constructs,
in which the NS5B gene was replaced by the corresponding
sequences derived from clinical isolates of various genotypes
(Ludmerer et al., 2005; Middleton T, Lim HB, Pilot-
Mathias T, Tripathi R, Roth A, Koev G, Ng T, Lu L,
Pithawalla R, Chen C-M, Kati W, Mo H, Di Bisceglie AM
& Molla A (2004) Development of a replicon-based shuttle
vector system for phenotypic characterization of HCV
patients NS5B genes towards polymerase inhibitors. 11th
International Symposium on Hepatitis C Virus & Related
Viruses). As discussed below, these reagents are beginning to
be used in order to define the spectrum of activity of various
NS5B inhibitors.
Equally important has been the implementation of
experimental procedures for selecting and characterizing
mutants resistant to specific inhibitors of the HCV
enzymes (Trozzi et al., 2003). This advance was made
possible by the use of HCV replicons expressing NPT and
was based on two replicon features. First, the low fidelity of
replicon replication in tissue culture causes the accumula-
tion of mutations resulting in a genetic diversity sufficient
to mimic the complexity of the HCV quasispecies in
patients. Second, the ability of the replicon cells to survive
in the presence of neomycin relies on replicon-driven
expression of NPT. Therefore, inhibitors of viral replication
abolish resistance to neomycin. Taking advantage of these
features, it is possible to select cell clones containing resis-
tant replicons by culturing a relatively small number of cells
in the presence of neomycin and of a given inhibitor. Under
these conditions, cells containing replicons sensitive to the
inhibitor succumb to the antibiotic’s toxic effect, while cells
containing mutant replicons with decreased sensitivity to
the inhibitor survive and give rise to colonies that can be
isolated, expanded and characterized. To date, it has been
possible to select replicons resistant to several inhibitors of
the NS5B polymerase, making it likely that this selection
procedure will be broadly applicable to all HCV replication
inhibitors. For all NS5B inhibitors described so far, resis-
tance mutations mapped in the NS5B coding sequence and
their role was easily defined by reverse genetic analysis.
Indeed, the availability of adapted replicon variants and of
highly permissive cell lines greatly facilitated the genetic
dissection of resistance mutations and also allowed the
study of the effect of these mutations on replication fitness.
In addition, dissection of the role played by resistance
mutations in the context of the recombinant NS5B poly-
merase has adequately complemented the genetic data
obtained with the mutant replicons. In fact, mutant
enzymes and replicons turned out to be complementary
tools for mechanistic studies and cross-resistance analysis.
Even more importantly, the biochemical characterization
of resistant enzymes and the possibility of modelling resis-
tance mutations in the 3D structure of the enzymes have
greatly contributed to the understanding of resistance
mechanisms.
Although resistance studies with authentic HCV viruses
cannot yet be performed, the breadth of data that can be
obtained with the current in vitro systems makes it likely
that the resistance patterns observed in vitro will also be
observed in vivo and should contribute to the identification
and clinical development of resistance-repellent inhibitors.
Inhibitors of the NS5B polymerase: mecha-
nisms of action and resistance studies
Inhibitors of viral polymerases have been extremely
successful in controlling chronic viral infection (De Clercq,
2004). It is therefore not surprising that efforts to develop
novel anti-HCV therapeutics have focused on the identifi-
cation of low molecular weight inhibitors of the HCV
NS5B polymerase. These efforts have resulted in the iden-
tification of several classes of NS5B polymerase inhibitors,
the most advanced of which are being evaluated in clinical
trials. In the following section, we will discuss those
inhibitors for which resistance studies have been reported.
For the purposes of this review, NS5B inhibitors are
divided into two categories according to their binding site
on the enzyme: active site inhibitors and allosteric
inhibitors.
Active site inhibitors
Based on their chemical structure, active site inhibitors can
in turn be divided in two subcategories: nucleoside
inhibitors (NIs), that inhibit the enzyme as substrate
analogues, and active site non-nucleoside inhibitors (NNIs)
that inhibit the enzyme as mimics of the pyrophosphate
product. With the notable exception of RBV, most, if 
not all, NIs of the NS5B polymerase function as chain
232 ©2005 International Medical Press
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terminators, that is they are incorporated in the nascent
RNA molecule and prevent incorporation of the following
nucleotide.
Nucleoside inhibitors: ribavirin
RBV (Figure 3A, [1]) is a guanosine analogue with a
broad-spectrum antiviral activity (McHutchison & Patel,
2002). Though RBV is a mainstay of the approved combi-
nation therapies for HCV infection, its mechanisms of
action are currently not fully understood (Lau et al., 2002).
RBV has been proposed to exert its activity through one or
more of the following mechanisms: i) enhancement of the
immune response; ii) inhibition of the enzyme inosine
monophosphate dehydrogenase, resulting in a decreased
intracellular GTP concentration with the consequent
reduction of viral RNA synthesis; iii) inhibition of the viral
polymerase; iv) incorporation of the RBV monophosphate
in the viral RNA, resulting in an increased mutation rate.
The latter mechanism has received some support from a
series of in vitro experiments. Biochemical studies have
shown that RBV triphosphate is accepted as a substrate by
the NS5B polymerase and is incorporated as monophos-
phate in the nascent RNA, although affinity for the
enzyme and incorporation rate are lower than those
measured for natural nucleotides (Maag et al., 2001; Bougie
& Bisaillon, 2003). Furthermore, RBV has been shown to
increase HCV RNA mutation frequencies in the replicon
system as well as in a DNA-based HCV replication system
(Contreras et al., 2002; Zhou et al., 2003).
In line with these in vitro findings, Young et al. reported
that RBV had a modest mutagenic effect on HCV in vivo
(2003). The same authors also observed that viruses derived
from patients infected by genotype 1a HCV and treated
with RBV consistently accumulated mutation of residue
Phe415 of the NS5B polymerase into Tyr (F415Y). The
role of this substitution in resistance to RBV therapy was
investigated using the replicon system. Replicons derived
from the Con1 isolate already have a Tyr at position 415
and were poorly sensitive to RBV. Conversely, replicons
containing the reverse substitution Y415F in NS5B were
more sensitive to RBV, implying that this substitution
affected HCV response to RBV and indirectly suggesting
that in vivo RBV exerts its action by directly interfering
with the NS5B polymerase activity. Residue 415 of NS5B
is located on the inner surface of the thumb domain of the
polymerase. Molecular modelling and structure analysis
suggest that the F415Y substitution could narrow the puta-
tive RNA binding pocket. However, the mechanisms by
which the F415Y substitution induces resistance to RBV
are at the moment entirely speculative and await further
investigation. Interestingly, while genotype 1a HCV
isolates have a Phe at position 415, isolates of other geno-
types have a Tyr at this position, suggesting that genotype
1a viruses might be more sensitive to RBV therapy than
other genotypes.
Nucleoside inhibitors: 2′-modified nucleosides
Development of NIs of the NS5B enzyme has been
complicated by the fact that they are pro-drugs that require
conversion to the active triphosphate species by the cellular
machinery. For this reason, development of NIs for HCV
has required parallel structure-activity relationship (SAR)
studies aimed at determining the activity of the NIs in
replicon or surrogate cell-based assays and that of the
corresponding triphosphates in NS5B enzymatic assays.
These studies led to the identification of a number of 
2′-modified NIs of the NS5B polymerase that efficiently
inhibit HCV replication in tissue culture.
Two pyrimidine derivatives, 2′-C-methyl-cytidine
(NM107 from Idenix pharmaceuticals; Figure 3A, [2]) and
its 3′-valine ester (NM283 from Idenix pharmaceuticals,
Figure 3A, [3]) are the most advanced NIs in clinical devel-
opment. Interestingly, NM107 was originally identified as
an inhibitor of the HCV-related bovine viral diarrhoea
virus (BVDV) in a cell-based infection assay and was
subsequently shown to have modest activity in the HCV
replicon assay, despite being efficiently converted to the
triphosphate in replicon cells (Carroll, 2004; Standring et
al., 2003). The 3′-valine ester modification yields a pro-
drug with improved oral bioavailability. Indeed, pre-clinical
PK studies showed that NM283 was efficiently absorbed,
rapidly converted to NM107 in plasma and had a sustained
half life, making it suitable for once daily oral administra-
tion (Godofsky et al., 2004). More importantly, NM283
was shown to be efficacious in HCV-infected chimpanzees,
inducing a 10-fold reduction of HCV viraemia after 7 days
of daily treatment (Standring, 2003).
These data prompted the initiation of human Phase I/II
clinical trials to evaluate safety, PK and antiviral activity
(Afdhal et al., 2004). The trial included five cohorts of
patients infected by genotype 1 viruses that were adminis-
tered a single daily dose of 50, 100, 200, 400 and 800 mg of
NM283 for 15 days. Up to 400 mg/day, NM283 showed
dose-proportional systemic exposure and no significant
accumulation after the 15 days of dosing. NM283 was well
tolerated, with some transient gastrointestinal toxicity.
More importantly, treatment with NM283 resulted in a
dose-proportional antiviral activity, with an end-of-treat-
ment viral load reduction of approximately 10-fold in the
cohort receiving the highest dose. Although in all patients
viraemia returned to pre-treatment levels after stopping
therapy, the positive outcome of this initial trial encouraged
the initiation of Phase II trials in combination with pIFNs.
No resistance data have yet been reported for NM283.
However, mutants resistant to the 2′-C-methyl-purine
nucleosides described below were also resistant to NM107,
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making it likely that NM283 will share the same mechanism
of resistance (Migliaccio et al., 2003; Olsen et al., 2004).
Other 2′-modified NIs, such as 2′-O-methyl-cytidine
(2′-O-Me-C, Figure 3A, [4]), 2′-C-methyl-adenosine (2′-
C-Me-A, Figure 3A, [5]) and 2′-C-methyl-guanosine (2′-
C-Me-G) are clinically less advanced, but have been more
extensively characterized in vitro (Carroll et al., 2003;
Eldrup et al., 2004). In line with structural resemblance to
the natural nucleotide substrates, the triphosphates of these
NIs are recognised by the NS5B polymerase as substrate
analogues and are incorporated as monophosphate in the
nascent RNA chain (Carroll et al., 2003). Incorporation of
2′-modified NIs prevents the addition of other nucleotides
resulting in premature termination of RNA synthesis. The
mechanism of chain termination is not fully understood,
but molecular modelling suggests that 2′-modifications
affect the ribose conformation, resulting in incorrect posi-
tioning of the 3′-OH group thus blocking subsequent
nucleotide addition. As predicted, the ability of these
compounds to inhibit replication of HCV replicons corre-
lates with the levels of triphosphate formed inside the cell.
In replicon cells, as well as in primary human hepatocytes,
2′-C-Me-G and 2′-O-Me-C are converted to the corre-
sponding triphosphates much less efficiently that 2′-C-
Me-A, and therefore are less potent replicon inhibitors,
despite the superior or equivalent inhibition of the purified
NS5B polymerase.
Notwithstanding its potent replicon activity, 2′-C-Me-
A had poor oral bioavailability in rats, indicating that it was
not absorbed or metabolized. This observation raised the
question of whether this compound could have clinical
utility for HCV therapy. SAR of the base led to the identi-
fication of 7-deaza-2′-C-Me-A (Figure 3A, [6]), a nucleo-
side with comparable replicon activity, reduced cellular
toxicity and very promising PK profiles in pre-clinical
animal species, making it an attractive candidate for clinical
development (Olsen et al., 2004).
Interestingly, 2′-C-Me-purine nucleosides displayed
antiviral activity against HCV-related viruses and did not
inhibit human DNA and RNA polymerases, indicating
that the 2′-C-Me modification was sufficient to convert
the NTP substrates into specific inhibitors of RdRps of the
positive strand RNA viruses (Migliaccio et al., 2003; Olsen
et al., 2004). Consistent with these findings, 2′-C-Me-
nucleosides have been shown to inhibit a panel of NS5B
enzymes and replicons derived from different HCV geno-
types, indicating their potential to be developed as treat-
ment for all viral strains (Carroll et al., 2004; Ludmerer et
al., 2005). Nonetheless, in vitro selection of replicons resis-
tant to 2′-C-Me-A and 7-deaza-2′-C-Me-A has shown
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Table 1. Effect of NS5B mutations on replicon resistance and cross-resistance to NS5B polymerase inhibitors
Resistance to compound
Conservation
Mutation selected with NS5B mutation across genotypes [5]/[6] [8] [9]/[10] [11] [13]
2′-C-Me-nucleoside [5], [6]* S282T 99% Yes No No No No
Dihydroxypyrimidine [8]† P156L 89% No Yes No No No
G152E 100% No Yes No No No
Benzimidazole [9]‡ P495L 99% No No Yes No No
P495A 99% No No Yes No No
Benzothiadiazine [11]§ H95R 99% No No No Yes No
M414T 86% No No No Yes No
Y448H 100% No No No Yes No
C451R 52% No No No Yes No
G558R 97% No No No Yes ?
Thiophene [13]¶ L419M 78% No No No ? Yes
M423T 99% No No No No Yes
©2005 International Medical Press
*(Migliaccio et al., 2003; Olsen et al., 2004); †(Migliaccio et al., unpublished); ‡(Tomei et al., 2003); §(Tomei et al., 2004; Nguyen et al., 2003;
Mo H, Lu L, Pilot-Mathias T, Dekhtyar T, Masse S, Pithawalla R, Ng T, Pratt J, Donner P, Maring C, Randolph J, Klein L & Molla A (2004)
Identification and characterization of mutations conferring resistance to either a HCV RNA-dependent RNA polymerase or HCV serine pro-
tease inhibitor or both in vitro. 11th International Symposium On Hepatitis C Virus and Related Viruses); ¶(Migliaccio et al., unpublished; Le
Pogam S, Leveque VJP, Hang J, Rajyaguru S, Oshiro C, Klumpp K, Symons J, Cammack & Najera I (2004) In vitro selection and characterization
of Con1 replicons resistant to a thiophene-2-carboxylic acid, a new anti-HCV polymerase non-nucleoside inhibitor. 11th International
Symposium on Hepatitis C Virus and Related Viruses)
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that HCV can become resistant to these NIs (Migliaccio et
al., 2003; Olsen et al., 2004). So far, resistance to 2′-C-Me-
nucleosides has been reported to be due to a single muta-
tion in the NS5B polymerase, namely substitution of
Ser282 with Thr (S282T). Replicons and NS5B enzymes
carrying this mutation were shown to be selectively resis-
tant to 2′-C-Me-nucleosides and to their triphosphates,
respectively, but not to 2′-O-Me-nucleosides or to NNIs of
NS5B (Table 1).
In the context of the recombinant polymerase, the S282T
mutation was shown to confer resistance to 2′-C-Me-nucle-
osides by a combination of two mechanisms. First, the
S282T mutant enzyme has a reduced affinity for 2′-C-Me-
nucleosides and only a modest decrease in affinity for the
natural substrates, thus reducing the frequency of 2′-C-Me-
nucleosides incorporation. Second, although inefficiently,
the S282T mutant enzyme can extend the nascent RNA
chain after incorporation of 2′-C-Me, thus overcoming
chain termination. Modelling of the 2′-C-Me-nucleoside in
the NS5B initiation complex provides initial hints on the
molecular mechanism of S282T-induced resistance. When
the 2′-C-Me-nucleoside is modelled in the NTP site, the 2′-
C-Me group is in close proximity of Ser282. Based on this
proximity, it is conceivable that the extra methyl group of
Thr might account for the reduced affinity for 2′-C-Me-
substituted nucleosides of the enzyme carrying the S282T
substitution. The ability of S282T NS5B to elongate 2′-C-
Me-primed nucleosides is not explained by the model, and
may depend on the influence of the S282T mutation on the
NS5B structure.
In line with the activity against several HCV isolates,
Ser282 is highly conserved across HCV genotypes, possibly
explaining the finding that replicons into which the S282T
mutation is introduced are attenuated in transient replication
assays. The fact that some of the originally selected replicons
replicated at a level comparable to wild-type suggests the
existence of as yet unidentified compensatory mechanisms
(Migliaccio et al., 2003). It remains to be defined whether
the S282T mutation will have similar debilitating effects on
HCV replication also in a more physiological setting, as well
as in the context of other viral sequences.
Active site non-nucleoside inhibitors: diketo
acids and pyrimidines
α-γ-diketo acids were recently identified as potent, specific
and reversible inhibitors of HCV NS5B polymerase
(Summa et al., 2004b). A representative member of this
inhibitor class is [7] (Figure 3B). The structure of
compounds from this class can be viewed as bipartite. The
diketo acid moiety has the potential to bind the HCV
RdRp by chelating the two Mg++ ions found in the enzyme
active site, thus constituting an active site ‘warhead’ or
anchor. Conversely, the aromatic substituent(s) in the 
left-hand side of the molecule can be substituted to
improve the inhibitor’s specificity and potency (Summa et
al., 2004b).
Inhibition of the polymerase enzymatic activity via the
chelation of the active site Mg++ ions has been reported as
the mechanism of inhibition of pyrophosphate analogues,
such as Foscarnet and phosphonoacetic acid (Sundquist &
Oberg, 1979). These compounds are believed to bind to the
pyrophosphate binding site of the enzyme, thus acting as
product-like inhibitors of the polymerase reaction.
Experiments aimed at measuring the combined effect of
diketo acids and classical pyrophosphate analogue(s) on the
HCV polymerase have indicated that the two classes of
inhibitors interact with the enzyme in a mutually exclusive
fashion, suggesting interaction with a common binding
site. For this reason, diketo acids are also referred to as
‘pyrophosphate mimics’ (De Francesco et al., 2003).
Compounds containing the diketo acid chelating moiety
have also been found to inhibit a variety of viral enzymes
that catalyse the Mg++-dependent transfer of a phosphoryl
group via the so-called two-metal-ion mechanism,
including the HIV and HBV polymerases, the influenza
virus endonuclease, the HIV integrase and HIV RNase H
(Grobler et al., 2002; Altamura et al., 2000; Hazuda et al.,
2000; Shaw-Reid et al., 2003; Tomassini et al., 1994). These
observations suggest that diketo acids have the potential to
inhibit a variety of metal-dependent phospho-transferase
enzymes that are of therapeutic interest. The potential to be
utilized as antiviral agents has been demonstrated for clas-
sical pyrophosphate analogues as well as for diketo acid
compounds. Foscarnet, a classical pyrophosphate analogue,
is used clinically as an anti-herpesvirus agent  (De Clercq,
2004). In addition, diketo acid inhibitors of HIV integrase
and influenza transcriptase have been reported that inhibit
viral replication in cell culture and in animal models
(Hazuda et al., 2000; Tomassini et al., 1994). However, no
diketo acids have thus far been identified that inhibit HCV
replication in cell culture.
Very recently, a new class of HCV polymerase inhibitors
was designed from a diketo acid and a meconic acid deriv-
ative discovered by screening. In this series, the diketo acid
warhead is replaced by dihydroxypyrimidine carboxylate
(Summa et al., 2004a) (Figure 3B, [8]). These are novel,
reversible, and selective inhibitors of the HCV NS5B poly-
merase that still utilize a Mg++-chelating moiety in order to
bind to the enzyme active site, but have improved drug-like
characteristics compared to the diketo acids. In fact, dihy-
droxypyrimidine carboxylates are inhibitors of RNA elon-
gation and are competitive with the classical pyrophosphate
analogues. As for the diketo acid series, the substitution of
the aryl group modulates the selectivity and potency also
for this new class of inhibitors (Summa et al., 2004a).
Compounds like [8] (Figure 3B) have been found to 
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efficiently inhibit replication of the HCV replicon in
cultured cells.
HCV replicons resistant to the inhibitory action of [8]
have been selected (Migliaccio et al., unpublished). The
characterization of these clones has revealed that either of
two specific mutations in the NS5B region of the HCV
genome is sufficient to confer resistance to this compound.
Specifically, substitution of Pro156 with either Ser or 
Leu, or substitution of Gly152 with Glu were found to
selectively confer resistance to [8] (Table 1). Pro156 and
Gly152 are located in the Λ2 fingertips loop, within the
NS5B RdRp active site channel, in line with the notion
that dihydroxypyrimidine carboxylates directly target the
enzyme active site (Figure 2). Molecular modelling data
suggest that the Λ2 loop is in close contact with the speci-
ficity portion of [8] but not with its metal chelating
portion, thus explaining how mutations in this region may
confer resistance without affecting the enzyme catalytic
center. Interestingly, this mechanism of acquired resistance
seems different from that observed for diketo acid
inhibitors of HIV integrase. In this latter case, mutations
that conferred resistance to diketo acid inhibitors mapped
in amino acids adjacent to the metal coordinating residues
of HIV-1 integrase (Hazuda et al., 2000).
Although not part of the enzyme catalytic core, Gly152
is conserved across all six major HCV genotypes. In
contrast, in HCV genotype 2a, Pro156 is replaced by Ala.
As a crucial step toward the identification of a pan-geno-
typic anti-HCV agent, it will be very important to deter-
mine whether or not this HCV strain is susceptible to
inhibition by dihydroxypyrimidine carboxylates.
Non-nucleoside allosteric inhibitors
Screening efforts by many different laboratories have
resulted in the identification and characterization of several
structural classes of allosteric NNIs. The majority of these
compounds have been reported to inhibit the HCV poly-
merase but not cellular polymerases or polymerases of other
viruses. In addition, compounds in each structural class
have been shown to block HCV replication in the replicon
system with no obvious cytotoxicity, highlighting the
potential for further development of several different
chemical scaffolds. The detailed mechanism of action of
the various classes of allosteric inhibitors has been reviewed
recently (De Francesco et al., 2003; Wu & Hong, 2003).
Here, we will discuss only those classes of inhibitors for
which resistance studies have been reported. Notably, in
contrast to the HIV reverse transcriptase for which all
known NNIs bind to the same site, genetic, biochemical
and structural data indicate that at least three different
binding sites exist for NNIs of the HCV polymerase.
Consequently, allosteric inhibitors of the HCV polymerase
are discussed below, based on their binding site on 
the enzyme.
Benzimidazoles/indoles
The first group of allosteric NNIs of the HCV RdRp
comprises a rather heterogeneous series of compounds
based on a benzimidazole or indole core. The initial tri-
substituted benzimidazole leads were discovered by high-
throughput screening of proprietary compound collections
at Boehringer-Ingelheim and Japan Tobacco (Hashimoto
et al., 2001; Beaulieu et al., 2004a). Significant increase in
potency was achieved by varying the substituents of the
benzimidazole scaffold. Compounds like [9] (Figure 4A)
are both potent inhibitors of the isolated NS5B enzyme
and of HCV replicons (Beaulieu et al., 2004a; Tomei et al.,
2003). In fact, Japan Tobacco has initiated Phase I/II clin-
ical trials with an oral compound ( JTK-003) presumably
based on a benzimidazole scaffold (McHutchison & Patel,
2002). Subsequent SAR studies, together with structural
information obtained by NMR and X-ray crystallography,
further defined the role of the different pharmacophore
elements and led to the development of a family of tetra-
substituted indoles, with sub-micromolar blockade of
HCV replicons (Figure 4A, [10]) (Beaulieu et al., 2004b;
Avolio et al., 2004; Harper et al., 2005; LaPlante et al.,
2004). These compounds are apparently devoid of the off-
target activities associated with the initial benzimidazole
leads and show encouraging PK profiles in pre-clinical
species, confirming the potential of this series for the devel-
opment of new anti-HCV agents.
Detailed analysis of their mechanism of action indicated
that compounds of this class act as allosteric inhibitors.
Through direct interaction with the enzyme at a single
binding site (LaPlante et al., 2004; McKercher et al., 2004;
Tomei et al., 2003), they inhibit RNA synthesis non-
competitively with respect to NTP substrates and interfere
with productive RNA binding. As suggested by single-
turnover studies, these compounds block RdRp activity
during a pre-elongation step, presumably impeding a
conformational transition needed for the formation of a
productive polymerase/RNA complex.
Replicons resistant to inhibition by benzimidazole-
based compounds have been selected by using potent
analogues, such as [9], that efficiently inhibit replication of
sub-genomic RNA in the cell-based assay (Tomei et al.,
2003). So far, a single NS5B substitution, Pro495 to Leu or
Ala (P495L/A), has been shown to selectively confer resis-
tance to this class of inhibitors (Table 1). Interestingly,
while the enzymes carrying either substitution of Pro495
retained full catalytic activity, replicons where these substi-
tutions were segregated did not replicate efficiently. In fact,
supplementary mutations, such as replacement of Ile585
with Thr (I585T), have been shown to compensate for the
L Tomei et al.
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[9] [10]
[11]
[12] [13] [14]
Enzyme IC50 280 nM
(Tomei et al. 2003)
Replicon IC50 350 nM
Enzyme IC50 26 nM
(Harper et al. 2005)
Replicon IC50 800 nM
Enzyme IC50 100 nM
(Dhanek et al. 2002)
Replicon IC50 550 nM
Enzyme IC50 1.5 µM
(Chan et al. 2004a)
Replicon IC50 0.8 µM(Wang et al. 2003)
Enzyme Ki 2.2 µM
(Love et al. 2003)
Enzyme IC50 0.9 µM
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Figure 4. Allosteric inhibitors of the NS5B polymerase. Shown are the structures of representative examples of
benzimidazoles/indoles (A), benzothiadiazines (B) and phenylalanines, thiophenes and dihydropyranones (C)
Enzyme and replicon IC50 or Ki values are derived from the indicated references.
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replication defect imposed by Pro495 substitutions. Pro495
is located in the thumb domain of NS5B (Figure 2) and is
conserved across natural HCV strains, suggesting a func-
tional role for this residue. X-ray crystallographic data indi-
cated that Pro495 is a key residue involved in the
interaction with a non-catalytic GTP molecule on NS5B
(Bressanelli et al., 2002). This finding, together with the
observation that high GTP concentrations antagonized
inhibition by benzimidazoles, led to the speculation that
the binding site for this class of inhibitors coincided at least
in part with the non-catalytic GTP-binding site (Tomei et
al., 2003). Indeed, the very recent elucidation of the struc-
ture of the polymerase in complex with representative
benzimidazoles or indoles showed that these inhibitors
bound the enzyme in a cavity of the thumb domain, on the
opposite side of Pro 495 with respect to GTP (Di Marco et
al., 2005; Coulombe et al., 2004). Intriguingly, in the apo-
protein the same cavity is occupied by the short α-helix A
at the extremity of the Λ1 fingertips loop and mediates the
interaction between the thumb and the finger domains. In
the inhibitor-bound structure, the α-helix A is displaced,
suggesting that the inhibitor can disrupt the fingertip-
thumb interactions, thus forcing the enzyme into an
‘unlocked’ conformation. Whether a ‘locked/unlocked’
conversion is required for productive template binding and
whether this conversion is affected by these inhibitors is a
fascinating hypothesis that remains to be proved.
Interestingly, despite the conservation of Pro495 across
all viral genotypes, representative benzimidazoles have
been found to be significantly less active on enzymes and
replicons derived from genotype 2 clinical isolates (Carroll
et al., 2004; Ludmerer et al., 2005). While the lack of inhi-
bition of genotype 2 isolates is probably due to other, yet
unidentified, differences between the NS5B polymerases, it
remains to be defined to what extent the lack of activity on
these isolates is specific for the tested compounds or
whether it is common to other compounds of the same
series.
Benzothiadiazines
A second class of allosteric inhibitors of the HCV poly-
merase is based on a benzothiadiazine scaffold and was
initially identified by high throughput screening of the
GlaxoSmithKline proprietary compound collection (Figure
4B, [11]) (Dhanak et al., 2002; Dhanak et al., 2001).
Representative compounds from this class have been thor-
oughly characterized in biochemical assays and in the
replicon system (Dhanak et al., 2002; Gu et al., 2003;
Johnston et al., 2003; Tomei et al., 2004). In common with
the benzimidazole/indole derivatives, compounds from the
benzothiadiazine class have been shown to interact directly
with the NS5B polymerase, to be non-competitive with
respect to the NTP substrates and to inhibit RNA
synthesis, acting prior to the formation of an elongation
complex (Dhanak et al., 2002; Gu et al., 2003; Tomei et al.,
2004). In contrast to benzimidazoles, however, benzothia-
diazines were less potent on deleted forms of the poly-
merase lacking the β–hairpin or the C-terminal domain
(Tomei et al., 2004). Furthermore, synergistic inhibition of
the polymerase by representative compounds of the two
classes and other subtle differences in in vitro assays
suggested that benzimidazoles and benzothiadiazines bind
the enzyme at different sites and possibly act via different
mechanisms (Tomei et al., 2004). This hypothesis was
strengthened by the different pattern of resistance muta-
tions and by the lack of reciprocal cross-resistance between
benzothiadiazine and benzimidazoles (Nguyen et al., 2003;
Tomei et al., 2004; Mo H, Lu L, Pilot-Mathias T,
Dekhtyar T, Masse S, Pithawalla R, Ng T, Pratt J, Donner
P, Maring C, Randolph J, Klein L & Molla A (2004)
Identification and characterization of mutations conferring
resistance to either a HCV RNA-dependent RNA poly-
merase or HCV serine protease inhibitor or both in vitro.
11th International Symposium on Hepatitis C Virus &
Related Viruses, Heidelberg, Germany). Five different
single NS5B mutations have been reported to induce resis-
tance to benzothiadiazines, namely substitution of His95
with Arg (H95R), Met414 with Thr (M414T), Tyr448
with His (Y448H), Cys451 with Arg (C451R) and Gly558
with Arg (G558R) (Table 1). Notably, comparison of repli-
cons and enzymes carrying these resistance mutations
contributed towards clarifying the mechanism of inhibition
of the benzothiadiazines. In fact, analysis of the mutant
replicons confirmed that all mutations were associated with
a resistant phenotype. Unexpectedly, replicons containing
C451R or G558R became ‘inhibitor-dependent’, showing
significant levels of replication only in the presence of
benzothiadiazines. In biochemical assays, only the M414T
mutant enzyme demonstrated clear resistance to inhibition,
while the enzymes containing the H95R, C451R and
G558R mutations had no or marginal changes in their
sensitivity to inhibition. This discrepancy, together with the
observation that the mutated amino acids lie in different
regions of the polymerase (Figure 2), suggested the exis-
tence of multiple mechanisms of resistance and provided a
first indirect clue towards identification of the benzothiadi-
azines binding site on the enzyme. Indeed, only the mutant
M414T enzyme lost the ability to interact with benzothia-
diazines in a direct binding assay, indicating that only for
this mutant was resistance due to reduced affinity for the
inhibitor and suggesting that Met414 might be part of the
inhibitor binding site. The location of Met414 on the inner
surface of the thumb domain, close to the active site,
provided additional evidence that the benzothiadiazine
binding site was distinct from those of other allosteric
inhibitors (see respective sections). Conversely, the other
L Tomei et al.
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mutations were proposed to induce resistance with
different mechanisms. The C451R/Y448H and G558R
mutations are located in the β-hairpin and C-terminal
region, respectively, confirming the results obtained with
deletion mutants and suggesting that these mutations
might affect the interaction of these structural elements.
The altered interaction of the β-hairpin/C-terminal region
might lead to decreased inhibition by benzothiadiazines
and also explain why replicons containing C451R or
G558R do not replicate efficiently in the absence of
compound. Finally, the mechanism of inhibition arising
from the H95R mutation remains speculative. Since His95
has been implicated in binding the RNA template
(O’Farrell et al., 2003), it has been proposed that replace-
ment of this residue in vivo might influence the ability of
the polymerase to recognize the viral genome in a way not
reproduced in the available biochemical assays. Taken
together, the characterization of resistant mutants
confirmed and extended the model for the mechanism of
inhibition by benzothiadiazines that emerged from
biochemical dissection and replicon studies. In this model,
benzothiadiazines bind to the enzyme near Met414 and
inhibit polymerase activity through a true allosteric mech-
anism, possibly by altering the distribution of enzyme
between an active and an inactive conformation.
Sequence analysis of natural HCV isolates revealed that
two NS5B residues involved in resistance to benzothiadi-
azines, M414 and C451, are not entirely conserved among
HCV genotypes, implying that some naturally occurring
HCV isolates might be resistant to this class of inhibitors.
In line with this consideration, representative benzothiadi-
azines have been found to inhibit only a limited subset of
enzymes and replicons derived from clinical isolates of
different genotypes (Ludmerer et al., 2005; Carroll et al.,
2004). However, it is not yet clear whether the lack of
activity on these isolates is specific for the tested
compounds or if it is a class effect and whether it is 
due to the resistance mutations identified for the 1b
replicon/enzyme or to other differences in the NS5B 
polymerase.
Thiophenes, phenylalanines and
dihydropyranones
The third group of allosteric inhibitors of the HCV poly-
merase is more heterogeneous and comprises compounds
with different chemical structures, namely thiophene,
phenylalanine and dihydropyranone derivatives (Figure
4C, [12], [13] and [14]). Despite the dissimilarities of their
chemical structures, these three classes of allosteric
inhibitors can be grouped together based on the crystallo-
graphic evidence that they bind the enzyme at the same site
(Biswal et al., 2005; Love et al., 2003; Wang et al., 2003).
Thiophene and phenylalanine derivatives have been 
identified by high throughput screening of the Shire
BioChem proprietary compound collection while dihy-
dropyranones were identified by a similar approach at
Agouron/Pfizer (Chan et al., 2004a; Chan et al., 2004b;
Love et al., 2003; Wang et al., 2003). For these structural
series, subsequent SAR studies have led to the identifica-
tion of compounds with potent activity in polymerase
assays. Similarly to the other allosteric inhibitors discussed
above, these compounds act as reversible inhibitors of the
NS5B polymerase and are not competitive with NTP
substrates. What is not known is whether they act only at a
step preceding elongation or if they also inhibit polymer-
ization. The structure of the polymerase in complex with
representative compounds of each of these three chemical
series was determined by co-crystallization of enzyme and
inhibitors (dihydropyranone) or by soaking apoprotein
crystals in inhibitor solutions (phenylalanines and thio-
phenes). Crystallographic data established that these three
types of inhibitors bind in a long cleft at the base of the
thumb domain, ~35 Å away from the active site (Biswal et
al., 2005; Love et al., 2003; Wang et al., 2003). Comparison
of the polymerase structures with and without inhibitors
indicates that, in contrast to benzimidazoles/indoles, the
inhibitor binding pocket is occupied by the solvent in the
native polymerase structure. Interestingly, while dihydropy-
ranone or phenylalanine binding does not induce major
rearrangements of the polymerase structure, binding of
thiophene inhibitors causes a conformational change of the
enzyme toward an open form (Biswal et al., 2005).
Comparison of the binding mode highlights similarities
and differences in the interactions established by the three
classes of compounds with the enzyme. The cyclopentyl
moiety of the dihydropyranone, the dichlorophenyl group
of the phenylalanines and the benzoyl substituent of thio-
phenes occupy the hydrophobic pocket formed by Leu419,
Arg422, Met423, Leu474, His475, Tyr477 and Try528,
while the charged groups of compounds form direct or
water-mediated hydrogen bonds with Ser476 and Tyr477.
The remaining moieties of the compounds contact
different areas of the protein surface, underlining the
promiscuous features of this binding site.
Interestingly, the hydrophobic pocket targeted by these
compounds is relatively highly conserved among HCV
genotypes, displaying only a few conservative substitutions
that are not expected to interfere with inhibitor binding
(Wang et al., 2003). Surprisingly, initial profiling of thio-
phene derivatives on replicons and enzymes derived from
different viral isolates is only partially in agreement with
this hypothesis. In fact, compounds of this class have been
reported to retain activity on several replicons expressing
genotype 1 polymerases but to be significantly less potent
on polymerases of genotypes other than 1 (Ludmerer et al.,
2005; Carroll et al., 2004). Thus far, limited resistance
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studies have been reported on representative thiophene
derivatives (Migliaccio et al., unpublished).
Two different single NS5B mutations have been
reported to induce resistance to thiophene inhibitors –
substitution of Leu419 with Met (L419M) or substitution
of Met423 with Thr (M423T). Based on the location of
Met423 and Leu419 in the hydrophobic region of the
inhibitors’ binding site, it is speculated that substitutions of
these residues significantly alter the binding site and thus
induce resistance by reducing the enzyme affinity for the
inhibitors. Although the full resistance and cross-resistance
pattern of these mutants has yet to be determined, prelim-
inary data indicate no or limited cross-resistance with
nucleoside, benzimidazole and benzothiadiazine inhibitors
(Table 1).
Conclusions and future outlook
The identification of inhibitors of the HCV polymerase
that efficiently block viral replication in tissue culture has
fostered the hope that these compounds will become effec-
tive anti-HCV drugs in the near future. Indeed, an NS5B
NI has shown promising results in clinical trials, and effi-
cacy studies in humans have been announced for other
compounds. The enthusiasm has been partially curtailed by
recent in vitro evidence that HCV genetic variability repre-
sents a serious hurdle for the clinical success of HCV poly-
merase inhibitors. Though the relevance of these initial
results requires confirmation from more physiological in
vivo studies, it is likely that they will impact the direction
of drug discovery efforts. Indeed, these in vitro studies have
fully confirmed the suspicion that the HCV genetic vari-
ability is a major determinant of the ability of various
classes of polymerase inhibitors to block viral replication.
Preliminary profiling of prototype compounds on different
viral isolates revealed remarkable differences in activity,
especially in the case of allosteric inhibitors. Along the
same lines, selection experiments have demonstrated that,
at least in tissue culture, HCV can become resistant to
every class of polymerase inhibitor identified thus far.
Comparison of the available data highlights similarities
and differences between the diverse classes of NS5B poly-
merase inhibitors. Notably, for all inhibitors analysed so far,
a single mutation in the polymerase is apparently sufficient
for in vitro resistance. Yet, while resistance to 2′-C-Me
nucleosides and benzimidazoles is apparently due to 
mutations of one unique residue, mutations of numerous
residues have been reported to confer resistance to other
NNIs (Table 1). In addition, quantitative data have not
always been reported and it is likely that the degree of 
resistance will not be the same for all mutations. Further,
while the majority of mutations had minimal effects on
replication, the substitutions of Ser282 or Pro495 have
been shown to have a negative effect on replicon fitness 
and presumably require additional ‘compensatory’ muta-
tions. Finally, each class of inhibitors elicits a different set
of resistance mutations that show limited, if any, cross-
resistance, while cross-resistance is in general the rule
within the same structural class (Table 1). This finding
indicates that inhibitors with different mechanisms of
action can be considered as acting on different targets and
therefore have the potential to be developed for combina-
tion therapy.
Based on all available data, it could be predicted that
allosteric inhibitors will likely be effective only on some
viral isolates or genotypes. Similarly, these data indicate
that the possibility for resistance arising in the clinic exists
for all classes of polymerase inhibitors, although some
classes are likely to show a higher genetic barrier to resis-
tance development. However, it is obviously too early to
draw firm conclusions, since the majority of studies
reported so far have been performed with prototype
compounds that may not reflect the results that will be
obtained with more potent and optimized inhibitors.
Furthermore, resistance mutants have been selected with
only a couple of viral isolates and therefore it is difficult to
anticipate whether comparable resistance patterns will be
observed in different genetic contexts. Given the different
requirements for replication in vitro and in vivo, it is not
immediately obvious if the debilitating effect of some resis-
tance mutations on replicon fitness will translate into a
similar effect on HCV replication in humans. Lastly,
inhibitors have been profiled only on a relatively small
number of isolates, making it difficult to generalize the
results of these studies. For the same reason, it is not yet
possible to identify with certainty the molecular determi-
nants of the difference in activity between viral isolates.
Only in some cases is it likely that the difference in potency
reflects a variation of residues affected by resistance 
mutations.
What will be the impact of these results on drug devel-
opment and what should we expect for the future? In our
opinion, these initial results strongly argue for the necessity
to perform resistance studies and profile inhibitors against
a variety of viral isolates even at early stages of inhibitor
development.
Based on the current knowledge and methodologies, it is
already possible to use the information obtained from in
vitro resistance studies to assist inhibitor development and
to broaden their spectrum of activity on different viral
isolates. Indeed, by simply profiling inhibitors against a
limited number of natural variants and resistant mutants it
is possible to predict the breadth of activity of a given
inhibitor and obtain information on the mechanism of
action and the site of binding on the enzyme. In addition,
comparison of related compounds on sensitive and resistant
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viral variants can provide crucial information on the mech-
anisms and the determinants of resistance that, together
with biochemical and structural data, contribute to the
design of improved inhibitors.
In the case of HIV, enough data have been accumulated
to predict the chance of therapeutic response to most
classes of drugs based on the viral sequence. These data are
currently used to tailor therapy and also to assist the 
development of new drugs. In comparison, the field of
HCV resistance to antiviral agents is still in its infancy,
though it is growing up at a rapid rate. Considering that
much of the information reported in this review has yet to
appear in press, we suspect that the results we have seen so
far represent only the tip of the iceberg and we expect to see
HCV resistance studies increasingly published in the near
future. Hopefully, these forthcoming results will contribute
to deciphering the molecular determinants of inhibitor
activity and will provide the key for predicting the proba-
bility of therapeutic response to the NS5B inhibitors.
The documented emergence of in vitro resistance to
inhibitors of the NS5B polymerase – as well as to inhibitors
of the NS3-4A protease (Lin et al., 2004) - will probably
have decisive bearing on the clinical development pathways
of direct anti-HCV agents. In the near future these agents
will probably be developed in combination with IFN or
IFN and ribavirin. This is already the case for the NS5B
inhibitor NM283. Once more agents are available, it will
become possible to conceive new combination schemes.
Considering that one of the major limitations of current
therapies is the severity of the side effects, it would be
desirable to shift away from the current drugs and develop
combinations of therapies based entirely on novel antiviral
agents. Whether these combinations will be sufficient to
effectively treat HCV patients remains an open question
that will hopefully be answered soon.
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